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Background/introduction
We describe the experience of the HIFU Surgical Oncology
Unit of Hospital University Mutua Terrassa (Barcelona,
Spain) treating malignant tumors. We analyze results in
unresectable pancreatic tumors treated with USgHIFU
hyperthermic ablation plus adjuvant chemotherapy.
Methods
From February 2008 to April 2014 we have treated 148
malignant cases. Of those, 48 cases of non resectable pan-
creatic tumors were treated from March 2010 to April
2014, and we include the first 43 patients to the analysis
(until December 2013). All of them underwent systemic
chemotherapy with a standard combination. Clinical
responses (thermical ablation achieved) were measured
by image techniques. They were 29 Stage III cases and
14 Stage IV cases. Complications were also analyzed.
Results and conclusions
The distribution of the 148 cases treated reflects a major-
ity of pancreatic and liver tumors. We analyze the 43
pancreatic tumors. Clinical responses (ablation obtained)
were 82% in all cases, sustained at 8 weeks of the proce-
dure. We obtained 11 complete responses (25%) at the
end of the combined treatment, 9 from stage III patients
and 2 from stage IV. Major complications included
severe pancreatitis with GI bleeding (1), skin burning
grade III that required plastic surgery (2). No deaths
due to the procedure were registered. Overall Median
Survival is 16 month (6 mo – 3.4 year) Conclusions:
HIFU is a potentially effective and safe modality for
the treatment of malignant tumors. Compared with
published data, HIFU proves survival advantage in non
resectable stage III and IV pancreatic cancer.
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